AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16119233 — intervention group
Group type: EXPERIMENTAL
Intervention: Berkner transform-based multiscale detector for genioglossus EMG reflex
Number of subjects: 0
Study 12372663 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of nicotine administered by nasal spray
Number of subjects: 55
Study 10411037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (treatment group)
Number of subjects: 76
Study 10411037 — intervention group
Group type: COMPARATOR
Intervention: Delay group (control)
Number of subjects: 76
Study 7475198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Metoprolol (n = 34)
Number of subjects: 70
Study 7475198 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (n = 36)
Number of subjects: 70
Study 2137717 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser group
Number of subjects: 50
Study 2137717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 7419336 — intervention group
Group type: COMPARATOR
Intervention: Total fasting (TF)
Number of subjects: 25
Study 7419336 — intervention group
Group type: COMPARATOR
Intervention: 80 kcal-PSMF (17 g protein=2.6 g N)
Number of subjects: 25
Study 7419336 — intervention group
Group type: COMPARATOR
Intervention: 180 kcal-PSMF (40 g protein=6.4 g N, 2 g fat)
Number of subjects: 25
Study 7419336 — intervention group
Group type: COMPARATOR
Intervention: 80/180 kcal-PSMF (80 kcal for 1st and 2nd week, 180 kcal for 3rd and 4th week)
Number of subjects: 25
Study 31759229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task intervention (recalling threat memory while performing a secondary task)
Number of subjects: 75
Study 31759229 — intervention group
Group type: COMPARATOR
Intervention: Recall only task (without the dual-task)
Number of subjects: 75
Study 31759229 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 75
Study 30285795 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic pulmonary vein ablation
Number of subjects: 21
Study 30285795 — intervention group
Group type: COMPARATOR
Intervention: Catheter pulmonary vein ablation
Number of subjects: 21
Study 27667330 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief one‐to‐one education
Number of subjects: 321
Study 27667330 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 321
Study 27667330 — intervention group
Group type: EXPERIMENTAL
Intervention: If participants who attempted vaccination had received the vaccine
Number of subjects: 321
Study 25271984 — intervention group
Group type: EXPERIMENTAL
Intervention: Laetiporus sulphureus (LS)
Number of subjects: 61
Study 25271984 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametes versicolor + Ganoderma lucidum (TV+GL)
Number of subjects: 61
Study 21331065 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater intake of saturated fat at 6 months
Number of subjects: 810
Study 21331065 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater intake of plant protein at 6 months
Number of subjects: 810
Study 21084608 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental changes in effective connectivity underlying inhibitory control (antisaccade task)
Number of subjects: 0
Study 21084608 — intervention group
Group type: COMPARATOR
Intervention: Reflexive responses (prosaccade task)
Number of subjects: 0
Study 18684256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation at the right midseptum
Number of subjects: 63
Study 18684256 — intervention group
Group type: COMPARATOR
Intervention: Ablation at the Rt-IS or PCS
Number of subjects: 63
Study 18684256 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior type tachycardia
Number of subjects: 63
Study 18684256 — intervention group
Group type: COMPARATOR
Intervention: Inferior type tachycardia
Number of subjects: 63
Study 15635208 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (face immersion test)
Number of subjects: 5
Study 12878742 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF enemas (5 microg in 100 ml of inert carrier)
Number of subjects: 12
Study 12878742 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF enemas
Number of subjects: 12
Study 11045236 — intervention group
Group type: EXPERIMENTAL
Intervention: Misinformation items
Number of subjects: 0
Study 11045236 — intervention group
Group type: COMPARATOR
Intervention: Non-misinformation items
Number of subjects: 0
Study 11045236 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual difference measures
Number of subjects: 0
Study 8803527 — intervention group
Group type: EXPERIMENTAL
Intervention: 76 mg disodium monofluorophosphate (MFP, equivalent to 10.0 mg F- ion)
Number of subjects: 13
Study 8803527 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg enteric-coated sodium fluoride (NaFor, equivalent of 11.3 mg F- ion)
Number of subjects: 13
Study 8803527 — intervention group
Group type: EXPERIMENTAL
Intervention: 22.1 mg sodium fluoride injection solution (NaFiv, equivalent to 10.0 mg F- ion)
Number of subjects: 13
Study 8803527 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 13
Study 1728720 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (25 U fast-acting insulin bolus followed by continuous infusion of 1 U/kg body weight for 1 hour)
Number of subjects: 18
Study 1728720 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 18
Study 6690344 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil (250 mg o.d.)
Number of subjects: 15
Study 6690344 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil (5 mg/kg)
Number of subjects: 15
Study 31805787 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVES intervention (patient global risk factor control report card, personalized phone text-messaging, educational video)
Number of subjects: 400
Study 31805787 — intervention group
Group type: COMPARATOR
Intervention: Control group (text messages, modest financial incentives)
Number of subjects: 400
Study 31805787 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVES intervention (for subgroup with baseline BP >140/90 mm Hg, n=168)
Number of subjects: 400
Study 31805787 — intervention group
Group type: COMPARATOR
Intervention: Control group (for subgroup with baseline BP >140/90 mm Hg, n=168)
Number of subjects: 400
Study 30514364 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched flours alone
Number of subjects: 100
Study 30514364 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched flours with prebiotics
Number of subjects: 100
Study 30514364 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched flours coupled with antibiotic treatment
Number of subjects: 100
Study 30514364 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 30514364 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental Milestones Checklist II (DMC II) questionnaire
Number of subjects: 100
Study 26431778 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB)
Number of subjects: 104
Study 26431778 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 104
Study 26092771 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study 26092771 — intervention group
Group type: COMPARATOR
Intervention: Control (imitated acupuncture procedure)
Number of subjects: 40
Study 23156122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling in the third trimester (education twice in the first month and once a month for the next 2 months)
Number of subjects: 115
Study 23156122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling in the third trimester
Number of subjects: 115
Study 23156122 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital advice (comparison group)
Number of subjects: 115
Study 21082306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chlorhexidine solution (CHX)
Number of subjects: 31
Study 21082306 — intervention group
Group type: COMPARATOR
Intervention: No chlorhexidine solution (no CHX)
Number of subjects: 31
Study 21082306 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisalign treatment
Number of subjects: 31
Study 19281091 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat Soft Mist Inhaler (SMI)
Number of subjects: 13
Study 19281091 — intervention group
Group type: COMPARATOR
Intervention: Hydrofluoroalkane (HFA)‐MDI
Number of subjects: 13
Study 19281091 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 13
Study 15852426 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 100
Study 15852426 — intervention group
Group type: COMPARATOR
Intervention: Proton-pump inhibitor (PPI) therapy
Number of subjects: 100
Study 12769404 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 0
Study 12769404 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical colchicine
Number of subjects: 0
Study 12769404 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinoids
Number of subjects: 0
Study 11783194 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianruling (JRL) treatment
Number of subjects: 0
Study 8709734 — intervention group
Group type: EXPERIMENTAL
Intervention: New programme of antenatal care (median 4 visits)
Number of subjects: 15994
Study 8709734 — intervention group
Group type: EXPERIMENTAL
Intervention: New programme of antenatal care
Number of subjects: 15994
Study 8709734 — intervention group
Group type: COMPARATOR
Intervention: Standard programme of antenatal care (median 6 visits)
Number of subjects: 15994
Study 8709734 — intervention group
Group type: COMPARATOR
Intervention: Standard programme of antenatal care
Number of subjects: 15994
Study 1869004 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine (0.1 mg/kg)
Number of subjects: 20
Study 1869004 — intervention group
Group type: COMPARATOR
Intervention: pethidine (0.8 mg/kg)
Number of subjects: 20
Study 6741674 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 6741674 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (two doses)
Number of subjects: 0
Study 31742447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit Moms/Mamás Activas intervention (internet-based weight loss program)
Number of subjects: 0
Study 30410987 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional endoscopy
Number of subjects: 0
Study 30410987 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional endoscopy
Number of subjects: 0
Study 27422656 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline health status assessment using EQ-5D-3L
Number of subjects: 539
Study 27422656 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up health status assessment 12 months later
Number of subjects: 539
Study 27422656 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of health utility scores over time
Number of subjects: 539
Study 27422656 — intervention group
Group type: EXPERIMENTAL
Intervention: Age comparison of health utility scores
Number of subjects: 539
Study 24519622 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexed at 90° during surgical closing (Group 2)
Number of subjects: 29
Study 24519622 — intervention group
Group type: COMPARATOR
Intervention: Knee extended during surgical closing (Group 1)
Number of subjects: 29
Study 24519622 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received the same anaesthesia method, surgical team, surgical technique, prosthesis type, and rehabilitation process.
Number of subjects: 29
Study 24519622 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic evaluation at 180°/s
Number of subjects: 29
Study 19694774 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental-aid intervention (n = 114)
Number of subjects: 457
Study 19694774 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (n = 111)
Number of subjects: 457
Study 19694774 — intervention group
Group type: COMPARATOR
Intervention: Class-work intervention (n = 115)
Number of subjects: 457
Study 19694774 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 117)
Number of subjects: 457
Study 15889510 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 65
Study 15889510 — intervention group
Group type: COMPARATOR
Intervention: Medication (Control)
Number of subjects: 65
Study 12352910 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF for 3 months, replaced by AZA for 9 months (Group 1)
Number of subjects: 477
Study 12352910 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF for 12 months (Group 2)
Number of subjects: 477
Study 12352910 — intervention group
Group type: COMPARATOR
Intervention: AZA for 12 months (Group 3)
Number of subjects: 477
Study 9327829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular injury treatment (angioplasty)
Number of subjects: 0
Study 7695066 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with birch pollen antigens in enterocoated capsules
Number of subjects: 30
Study 7695066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 3605563 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml 25% cocaine HCl combined with 0.1% adrenaline in paraffin paste
Number of subjects: 20
Study 3605563 — intervention group
Group type: COMPARATOR
Intervention: 1.0 ml 25% cocaine HCl in paraffin paste
Number of subjects: 20
Study 3605563 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 ml aqueous 4% cocaine HCl combined with 0.05% adrenaline
Number of subjects: 20
Study 3605563 — intervention group
Group type: COMPARATOR
Intervention: 4.0 ml aqueous 4% cocaine HCl on ribbon gauze
Number of subjects: 20
Study 3605563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine adrenaline paste
Number of subjects: 20
Study 3605563 — intervention group
Group type: COMPARATOR
Intervention: Plain cocaine paste
Number of subjects: 20
Study 3605563 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous cocaine adrenaline
Number of subjects: 20
Study 3605563 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cocaine alone
Number of subjects: 20
Study 31042441 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bracing
Number of subjects: 16
Study 31042441 — intervention group
Group type: COMPARATOR
Intervention: Passive placebo bracing
Number of subjects: 16
Study 31042441 — intervention group
Group type: COMPARATOR
Intervention: Unbraced
Number of subjects: 16
Study 31042441 — intervention group
Group type: COMPARATOR
Intervention: All tested conditions (active bracing, passive placebo bracing, unbraced)
Number of subjects: 16
Study 29181582 — intervention group
Group type: EXPERIMENTAL
Intervention: ceVUS with Optison™
Number of subjects: 30
Study 29181582 — intervention group
Group type: COMPARATOR
Intervention: VCUG
Number of subjects: 30
Study 27130202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide/albuterol (CVT-MDI)
Number of subjects: 226
Study 27130202 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (ALB-HFA)
Number of subjects: 226
Study 24465438 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (0.56 mg 5‐methyl‐tetrahydrofolate, 3 mg vitamin B6, 0.02 mg vitamin B12)
Number of subjects: 2501
Study 24465438 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 fatty acids (600 mg eicosapentaenoic and docosahexaenoic acids in a 2:1 ratio)
Number of subjects: 2501
Study 24465438 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins and n‐3 fatty acids combined
Number of subjects: 2501
Study 24465438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2501
Study 22142381 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infraclavicular brachial plexus (CIBP) block
Number of subjects: 33
Study 22142381 — intervention group
Group type: COMPARATOR
Intervention: Continuous stellate ganglion (CSG) block
Number of subjects: 33
Study 22142381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CIBP and CSG blocks
Number of subjects: 33
Study 20664561 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (140 g/day)
Number of subjects: 17
Study 20664561 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (50 g/day)
Number of subjects: 17
Study 17978064 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin, 500 mg/day for 28 days
Number of subjects: 45
Study 17978064 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular meglumine antimoniate, 10 mg Sb/kg/day for 28 days
Number of subjects: 45
Study 17978064 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular meglumine antimoniate (for patients who failed azithromycin)
Number of subjects: 45
Study 17978064 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate
Number of subjects: 45
Study 14762036 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (adjusted-dose, target INR 1.4-2.8)
Number of subjects: 1770
Study 14762036 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/d)
Number of subjects: 1770
Study 14762036 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LA and aCL antibodies positivity
Number of subjects: 1770
Study 11477460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (13.3 mg)
Number of subjects: 52
Study 11477460 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (8.2 mg)
Number of subjects: 52
Study 11477460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 10023273 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular paralysis achieved with pancuronium (Group 2)
Number of subjects: 18
Study 10023273 — intervention group
Group type: COMPARATOR
Intervention: No neuromuscular paralysis (Group 1)
Number of subjects: 18
Study 10023273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 18
Study 7831627 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (oral, twice daily doses, trough serum concentrations between 8.4 and 13.5 mg/l)
Number of subjects: 10
Study 7831627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7831627 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (inhalation of 800 micrograms)
Number of subjects: 10
Study 3241821 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 20 mg daily
Number of subjects: 7
Study 3241821 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg daily
Number of subjects: 7
Study 3241821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29660674 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline Personality Disorder (BPD) diagnosis
Number of subjects: 184
Study 29660674 — intervention group
Group type: COMPARATOR
Intervention: No BPD diagnosis (Control)
Number of subjects: 184
Study 29660674 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid BPD and Antisocial Personality Disorder (ASPD)
Number of subjects: 184
Study 29660674 — intervention group
Group type: COMPARATOR
Intervention: ASPD diagnosis only (Control)
Number of subjects: 184
Study 29660674 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD diagnosis only
Number of subjects: 184
Study 26888854 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 200
Study 26238480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon catheter ablation
Number of subjects: 41
Study 24228447 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.187% ropivacaine and fentanyl 3.2 microg x ml(‐1)
Number of subjects: 52
Study 24228447 — intervention group
Group type: COMPARATOR
Intervention: 0.187% levobupivacaine and fentanyl 3.2 microg ml(‐1)
Number of subjects: 52
Study 21185725 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE music during loaded sit-to-stand (LSTS)
Number of subjects: 23
Study 21185725 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation condition after PSE music
Number of subjects: 23
Study 21185725 — intervention group
Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 23
Study 18362823 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview administration of FACT-G
Number of subjects: 1195
Study 18362823 — intervention group
Group type: COMPARATOR
Intervention: Self-administration of FACT-G
Number of subjects: 1195
Study 17194269 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (up to 6 mg/day)
Number of subjects: 30
Study 17194269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14632294 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing method based on protocol 1 for upper abdomen
Number of subjects: 250
Study 14632294 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing method based on protocol 2 for chest
Number of subjects: 250
Study 14632294 — intervention group
Group type: COMPARATOR
Intervention: Standard scanning with constant tube current for upper abdomen
Number of subjects: 250
Study 14632294 — intervention group
Group type: COMPARATOR
Intervention: Standard scanning with constant tube current for chest
Number of subjects: 250
Study 11558625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin B12 (Tricortin 1000)
Number of subjects: 60
Study 11558625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9168442 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating doses of epirubicin
Number of subjects: 147
Study 9168442 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of epirubicin
Number of subjects: 147
Study 8465839 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 8
Study 8465839 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8
Study 8465839 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 8
Study 2871092 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 198
Study 2871092 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin and Tobramycin
Number of subjects: 198
Study 31630072 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct in-person communication with family members
Number of subjects: 146
Study 31630072 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct communication with a physician or nurse practitioner
Number of subjects: 146
Study 31630072 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal bedside updates by nurses
Number of subjects: 146
Study 31630072 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone calls to families
Number of subjects: 146